Literature DB >> 11331455

Overproduction of transforming growth factor-beta1 (TGF-beta1) is associated with adhesion formation and peritoneal fibrinolytic impairment.

L Holmdahl1, K Kotseos, M Bergström, P Falk, M L Ivarsson, N Chegini.   

Abstract

BACKGROUND: Reduction in peritoneal fibrinolytic capacity and increased transforming growth factor-beta1 (TGF-beta1) production are associated with adhesion development. This study investigated the expression of TGF-beta1 in peritoneal tissue, and possible correlation with components of the fibrinolytic system locally in peritoneal tissue.
MATERIALS AND METHODS: Peritoneal samples were taken from 22 patients at relaparotomy. Samples of adhesions were collected from 10 patients. The patients were categorized into different groups depending on the quantity and the quality of adhesions. TGF-beta1 and components of the fibrinolytic system in tissue extracts were assayed using enzyme-linked immunosorbent assays.
RESULTS: The concentration of active TGF-beta1 in peritoneal samples from patients with extensive adhesions was double (P <.01) that of healthy subjects, but the total levels of TGF-beta1 were similar (P =.63). In adhesion tissue, both active (P <.003) and total (P <.008) TGF-beta1 concentrations were more than twice as high as unaffected peritoneum. There was a significant correlation between the concentration of plasminogen activator inhibitor type 1 in peritoneal samples with active TGF-beta1 (P <.03, r = 0.693) and adhesion tissue with total TGF-beta1 (P =.001, r = 0.872). The other components of the fibrinolytic system did not correlate significantly with TGF-beta1.
CONCLUSIONS: These data indicate that an overexpression of TGF-beta1 is associated with adhesion formation, possibly through a mechanism involving local regulation of plasminogen activator inhibitor type 1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11331455     DOI: 10.1067/msy.2001.113039

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  28 in total

Review 1.  Prevention of peritoneal adhesions: a promising role for gene therapy.

Authors:  Hussein M Atta
Journal:  World J Gastroenterol       Date:  2011-12-14       Impact factor: 5.742

2.  Combined intraoperative administration of a histone deacetylase inhibitor and a neurokinin-1 receptor antagonist synergistically reduces intra-abdominal adhesion formation in a rat model.

Authors:  Michael R Cassidy; Alan C Sherburne; Stanley J Heydrick; Arthur F Stucchi
Journal:  Surgery       Date:  2015-03       Impact factor: 3.982

Review 3.  Adhesive small bowel obstruction: epidemiology, biology and prevention.

Authors:  Jo-Anne P Attard; Anthony R MacLean
Journal:  Can J Surg       Date:  2007-08       Impact factor: 2.089

Review 4.  Encapsulating peritoneal sclerosis in children.

Authors:  Constantinos J Stefanidis; Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2013-11-21       Impact factor: 3.714

Review 5.  Peritoneal damage: the inflammatory response and clinical implications of the neuro-immuno-humoral axis.

Authors:  Tarik Sammour; Arman Kahokehr; Mattias Soop; Andrew G Hill
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

6.  Peritoneal infusion with cold saline decreased postoperative intra-abdominal adhesion formation.

Authors:  Cheng-Chung Fang; Tzung-Hsin Chou; Geng-Shiau Lin; Zui-Shen Yen; Chien-Chang Lee; Shyr-Chyr Chen
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

Review 7.  Cytokine orchestration in post-operative peritoneal adhesion formation.

Authors:  Ronan A Cahill; H Paul Redmond
Journal:  World J Gastroenterol       Date:  2008-08-21       Impact factor: 5.742

8.  Postoperative peritoneal adhesion: an update on physiopathology and novel traditional herbal and modern medical therapeutics.

Authors:  Setareh Soltany
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-09-26       Impact factor: 3.000

9.  Histone deacetylase inhibitors decrease intra-abdominal adhesions with one intraoperative dose by reducing peritoneal fibrin deposition pathways.

Authors:  Michael R Cassidy; Alan C Sherburne; Holly K Sheldon; Melanie L Gainsbury; Stanley Heydrick; Arthur F Stucchi
Journal:  Surgery       Date:  2013-11-14       Impact factor: 3.982

10.  An FDA approved neurokinin-1 receptor antagonist is effective in reducing intraabdominal adhesions when administered intraperitoneally, but not orally.

Authors:  Rizal Lim; Jonathan M Morrill; Scott G Prushik; Karen L Reed; Adam C Gower; Susan E Leeman; Arthur F Stucchi; James M Becker
Journal:  J Gastrointest Surg       Date:  2008-08-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.